Inclusion Criteria:

- Pathologically confirmed pancreatic adenocarcinoma

- T1 - T4 or N0-N1 pancreatic adenocarcinoma

- ECOG performance status ≤ 2

- Male and female, aged ≥ 18 - 80 years

- Signed study-specific informed consent

- General condition considered feasible for chemoradiotherapy

- Hg > 9 g/dL

- Total WBC ≥ 3 X 10^9/L

- Absolute granulocyte count ≥ 1.5 X 10^9 /L

- Absolute lymphocyte count ≥ 0.5 X 10^9 /L

- Platelet count ≥ 100 X 10^9/L

- INR ≤1.5 within 7 days prior to starting study treatment

- aPTT ≤1.5 x ULN within 7 days prior to starting study treatment

- PT < 14s

- Serum bilirubin ≤ 1.5 x ULN

- ALP, ALT, AST ≤ 2.5 x ULN

- Serum Creatinine ≤ 1.5 x ULN or estimated CrCl > 30 ml/min

- Total Ca <2.6 mmol/L

Exclusion Criteria:

- Diagnosis of metastatic disease

- Primary tumor > 5 cm in maximum diameter on any imaging modality

- >3 involved lymph nodes as per staging CT and/or PET-CT

- Clear indication of involvement of duodenal wall on imaging or at time of endoscopy

- Evidence of peritoneal carcinomatosis, portal vein occlusion, ascites or involvement
of non-regional lymph nodes

- Histology clearly other than adenocarcinoma

- Disease cannot be radiographically assessed due to patient related contraindications
or due to lack of visible tumor on pre-treatment imaging

- More than 1 prior chemotherapy regimen for pancreatic cancer or treatment for >6
months

- Prior chemotherapy for other malignancies in past 12 months

- Prior radiotherapy exposure that would overlap the anticipated study treatment fields

- Treatment with any other investigational agent, within 30 days

- Prior chemotherapy for pancreatic cancer is permitted, although there should be 30
days between last dose and start of treatment on protocol

- Past or current history of other malignancies (except non-melanoma skin cancer or
carcinoma in-situ of the cervix) unless in complete remission for a minimum of 2
years from treatment start

- Clinically significant cardiovascular disease

- Known hypersensitivity to gemcitabine or 5-fluoruracil

- Serious, non-healing wound, ulcer or bone fracture

- Major surgical procedure or significant traumatic injury within 28 days (not
including endoscopic biopsy)

- Evidence of any other disease, metabolic dysfunction, physical examination finding or
laboratory finding giving reasonable suspicion of a disease or condition that
contraindicates the use of chemoradiotherapy or puts the patient at high risk for
treatment-related complications

- Life expectancy < 5 years

- Inability or unwillingness to comply with the protocol

- Active ulcerative colitis, Crohns' disease or systemic lupus erythematosus

- Diagnosis of scleroderma

- Active peptic ulcer disease or history of ulcers in the last 2 years

- Gastric outlet obstruction

- Hg < 9 g/dL

- Total WBC count < 3 X 10^9/L

- Absolute granulocyte count < 1.5 X 10^9 /L

- Absolute lymphocyte count < 0.5 X 10^9 /L

- Platelets < 100 x 10^9/L

- INR >1.5 within 7 days prior to starting study treatment

- aPTT > 1.5 x ULN within 7 days prior to starting study treatment

- PT time > 14s

- Serum bilirubin > 1.5 x ULN

- ALP, AST, ALT > 2.5 x ULN

- Serum Creatinine > 1.5 x ULN or estimated CrCl < 30 ml/min

- Total Ca > 2.6 mmol/L

- Pregnancy or lactation

- Positive serum pregnancy test within 7 days of starting study treatment in
pre-menopausal women and women < 2 years after the onset of menopause.

- Female participants that are of childbearing potential unwilling or unable to use
effective means of contraception while receiving the study interventions and 30 days
after receiving the last dose of study interventions

- Male participants ,unwilling or unable, or whose female partner is unwilling or
unable, to use effective means of contraception while the participant is receiving
the study interventions and 30 days after receiving the last dose of study
interventions